AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Friedreich's Ataxia

Recent research efforts aimed at curing Friedreich's Ataxia.

Last updated

Friedreich’s Ataxia

Overview

Friedreich’s ataxia (FA) is a rare inherited, autosomal-recessive disorder in which most affected people have expanded GAA DNA repeats in both copies of the FXN gene. These repeats reduce production of frataxin, a mitochondrial protein needed for normal cellular energy metabolism. FA usually begins in childhood or adolescence and progressively impairs balance, walking, coordination, speech, sensation, and strength; it can also cause scoliosis, diabetes, and potentially life-threatening cardiomyopathy. Disease severity and rate of progression vary, but cardiac disease remains a major contributor to premature mortality. GeneReviews: Friedreich Ataxia (ncbi.nlm.nih.gov)

There is no approved cure that corrects the underlying genetic defect or reliably restores lost nerve cells. Standard care combines multidisciplinary monitoring and treatment of cardiac disease and diabetes with physical, occupational, and speech therapy, mobility and communication aids, and management of scoliosis and other complications. In the United States, omaveloxolone (Skyclarys) is approved for adults and adolescents aged 16 years and older; it improves clinical function on average in a trial population but is not a frataxin-restoring or curative therapy. Clinical management guidelines FDA approval announcement (pmc.ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research activity has accelerated substantially since 2020, with approaches now ranging from improved mitochondrial resilience to direct frataxin protein replacement, FXN gene delivery, and experimental editing of the disease-causing repeat. The central question has shifted from whether frataxin deficiency can be modified to whether enough frataxin can be restored safely, durably, and across the heart, peripheral nervous system, spinal cord, and brain. Several programs have reached human studies, but no intervention has yet demonstrated that it can permanently correct the genetic cause and reverse the full multisystem disease; therefore, a curative therapy remains an important but unproven goal. Emerging drug and gene therapies review GeneReviews: Friedreich Ataxia (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

Gene replacement is the leading potentially one-time treatment strategy. LX2006 uses an adeno-associated virus (AAVrh.10) vector to deliver a functional human FXN gene intravenously, with an initial focus on FA cardiomyopathy. Its phase 1/2 study tests a single dose in people with cardiac involvement and follows participants for five years, reflecting both the potential durability and the need for long-term safety monitoring after AAV treatment. Preclinical work has strengthened the rationale: AAV8-mediated FXN delivery reversed cardiac deficits and improved survival in a mouse model, while newer “secretable frataxin” engineering achieved broad frataxin repletion and correction of cardiac and neurologic features in FA mice after a single cerebrospinal-fluid administration. LX2006 phase 1/2 trial AAV8 cardiac gene therapy study Secretable frataxin gene therapy (clinicaltrials.gov)

The gene-therapy field has also clarified a crucial safety issue: frataxin must be restored within a therapeutic range rather than simply maximized. In mouse models, high cardiac frataxin expression could rescue disease at moderate levels but caused mitochondrial and cardiac toxicity at much higher levels. This makes promoter design, vector dose, tissue targeting, immune management, and direct measurement of frataxin expression central challenges for any systemic gene-replacement cure. Frataxin overexpression toxicity study (pubmed.ncbi.nlm.nih.gov)

Gene editing aims more directly at the root cause. A 2020 proof-of-concept study used CRISPR-Cas9 to remove the expanded GAA repeat from patient-derived hematopoietic stem cells, increasing FXN expression in corrected cells. More recently, researchers used base editors—tools that change individual DNA letters without making a full double-strand DNA break—to introduce stabilizing interruptions into GAA repeats. In patient cells and an FA mouse model, this reduced repeat expansion in transduced tissues and in the central nervous system. These findings are important because they seek to make the pathogenic repeat less unstable, but they remain preclinical and have not yet shown that editing can safely reach all of the vulnerable tissues in people with FA. CRISPR correction in patient stem cells Base editing of GAA repeats (pmc.ncbi.nlm.nih.gov)

Frataxin protein replacement offers a reversible alternative to gene therapy. Nomlabofusp (CTI-1601) is a daily injected fusion protein designed to enter cells and deliver frataxin to mitochondria. In an ongoing open-label study, Larimar reported sustained increases in frataxin measured in skin and directional improvements in neurologic and functional measures versus a natural-history reference group; these are encouraging but uncontrolled findings and therefore cannot establish clinical efficacy. The company reported submission of the first module of a rolling U.S. biologics license application in June 2026 and planned a confirmatory phase 3 study. Nomlabofusp open-label update Nomlabofusp open-label study (investors.larimartx.com)

Small molecules remain valuable but are not cures. Omaveloxolone activates the Nrf2 cellular stress-response pathway and was the first FDA-approved FA treatment after the 48-week MOXIe trial showed a statistically significant average benefit on the modified Friedreich Ataxia Rating Scale (mFARS). Etravirine, a repurposed anti-HIV medicine proposed to increase frataxin, was reasonably tolerated in a small 2024 open-label phase 2 study and was associated with improved exercise workload and a slower change in ataxia scores, but placebo effects and the short treatment period prevent firm conclusions. MOXIe trial Etravirine phase 2 study (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The most advanced gene-replacement effort is Lexeo Therapeutics’ LX2006 program. The ongoing phase 1/2 study, sponsored by Lexeo, evaluates dose-escalated AAVrh.10-FXN treatment for FA cardiomyopathy. In 2026, Lexeo reported regulatory alignment on a planned SUNRISE-FA 2 registrational study intended to assess changes in left-ventricular mass and myocardial frataxin expression; these company-reported interim and regulatory updates are preliminary and should not be interpreted as proof of a cure or established cardiac benefit. LX2006 phase 1/2 trial Lexeo registrational-trial update (clinicaltrials.gov)

Nomlabofusp is being studied in adults in a long-term open-label study and in children and adolescents in a randomized short-term safety and pharmacokinetic study sponsored by Larimar Therapeutics. The pediatric study evaluates daily subcutaneous dosing in participants aged 2 to under 18 years, with safety, injection-site reactions, electrocardiography, and echocardiography among its key measures. Pediatric nomlabofusp study Nomlabofusp open-label study (clinicaltrials.gov)

Vatiquinone, developed by PTC Therapeutics, illustrates both progress and the difficulty of FA trials. The 146-participant MOVE-FA phase 2/3 trial did not meet its primary endpoint of a statistically significant difference in total mFARS at 72 weeks, although some secondary or subscale findings and longer-term external-control comparisons appeared favorable. The FDA subsequently concluded that substantial evidence of efficacy had not been demonstrated and requested another adequate, well-controlled study; PTC registered the planned phase 3 PROVE-FA study, estimated to begin on August 15, 2026. MOVE-FA results PTC 2026 filing PROVE-FA trial (clinicaltrials.gov)

Methodologies and Scientific Approaches

FA researchers use patient-derived fibroblasts, induced pluripotent stem cells differentiated into sensory neurons and cardiomyocytes, and multiple mouse models to test whether an intervention restores frataxin, mitochondrial function, iron-sulfur-cluster biology, resistance to oxidative stress, heart structure, or motor performance. Gene-therapy studies additionally use nonhuman primates to assess vector distribution and frataxin expression in relevant tissues before human dosing. Human frataxin quantification after gene therapy in primates AAV8 cardiac gene therapy study (pubmed.ncbi.nlm.nih.gov)

Clinical research increasingly combines neurological scales such as mFARS and SARA with timed walking, hand-function tests, cardiac imaging, wearable sensors, blood frataxin assays, and neurodegeneration biomarkers. FACOMS and EFACTS natural-history cohorts supply essential estimates of how different patient groups progress, while newer studies suggest that plasma neurofilament light and tau, as well as home wearable metrics, may help identify disease activity and treatment response. FACOMS natural-history study Plasma biomarker study Wearable-monitoring study (pmc.ncbi.nlm.nih.gov)

Leading Institutions and Funding

The field is driven by multinational clinical networks and specialist centers, including the FACOMS network in North America and Australia, the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS), and major academic groups at institutions such as the Children’s Hospital of Philadelphia and the University of Pennsylvania, University of South Florida, University College London, Murdoch Children’s Research Institute, and UMass Chan Medical School. EFACTS prospectively links clinical assessments with biological samples, while FACOMS has provided long-term progression data used to design and interpret therapeutic trials. EFACTS registry FACOMS natural-history study (clinicaltrials.gov)

Biotechnology companies are now major translational partners: Lexeo Therapeutics is advancing cardiac FXN gene therapy, Larimar Therapeutics is developing nomlabofusp protein replacement, Biogen markets omaveloxolone, and PTC Therapeutics continues vatiquinone development. Patient organizations remain unusually influential: the Friedreich’s Ataxia Research Alliance (FARA) funds grants from basic science through clinical research, with general awards up to $125,000 per year and selected translational awards up to $200,000 per year; FARA and the Muscular Dystrophy Association jointly awarded $300,000 in 2024 to a UMass Chan team pursuing gene-editing technology for FA. FARA grant program MDA–FARA gene-editing grant (curefa.org)

Strengths, Limitations, and Challenges

The strongest recent advance is that FA research now contains therapies aimed at the underlying frataxin deficit rather than only downstream symptoms. Protein replacement is adjustable and potentially reversible; AAV gene replacement could provide long-lived expression after one treatment; and base editing offers a conceptual route to altering the unstable GAA repeat itself. Natural-history cohorts, increasingly sensitive functional measures, and biomarkers have also made rare-disease trials more feasible than they were a decade ago. Base editing of GAA repeats FACOMS natural-history study (nature.com)

However, FA is a systemic disease, so a treatment that reaches the heart may not adequately reach dorsal-root-ganglion neurons, spinal pathways, cerebellar circuitry, or skeletal muscle. AAV vectors face dose-related toxicity, pre-existing immunity, limited redosing options, manufacturing constraints, and the risk of excessive frataxin expression; editing approaches must demonstrate precise delivery, durable benefit, and acceptably low off-target effects. Small and heterogeneous trial populations, slow progression, loss of ambulation in later disease, and reliance on external natural-history comparators can also make efficacy difficult to prove, as the vatiquinone regulatory outcome demonstrates. Frataxin overexpression toxicity study PTC 2026 filing (pubmed.ncbi.nlm.nih.gov)

Outlook and Future Directions

As of August 8, 2026, FA is closer to biologically targeted treatment than at any earlier point, but it is not close enough to claim that a cure is imminent. The most important milestones to watch are controlled clinical evidence that nomlabofusp improves meaningful outcomes beyond frataxin biomarkers, durable cardiac benefit and safety from LX2006, completion and results of PROVE-FA, and preclinical demonstrations that repeat editing can safely correct relevant nervous-system and cardiac tissues. A true cure will probably need to show both early restoration of frataxin and durable prevention—or reversal—of neurological and cardiac decline across the disease’s many affected tissues. Nomlabofusp open-label update Lexeo registrational-trial update PROVE-FA trial (investors.larimartx.com)

References

Don't see your disease? Request a report